Published: 6 January 2022
Author(s): Marco Caminati, Veronica Batani, Lucia Guidolin, Giuliana Festi, Gianenrico Senna
Issue: May 2022
Section: Letter to the Editor

Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction to Aspergillus fumigatus, mainly characterized by severe asthma symptoms, hyper eosinophilia in blood, lung and airways, elevated serum IgE levels, bronchiectasis, bronchial mucoid impaction and lung fibrosis [1]. As recently remarked, oral corticosteroids (OCS) and antifungal therapy currently represent the gold standard treatment [2]; however, despite their proven efficacy, they may cause severe side effects, especially in the case of prolonged therapy.

Newsletters

Stay informed on our latest news!